4-Methylcatechol stimulates apoptosis and reduces insulin secretion by decreasing betacellulin and inhibin beta-A in INS-1 beta-cells

Human & Experimental Toxicology
Ayse Karatug KacarSehnaz Bolkent

Abstract

Insulinoma INS-1 cell line is a pancreatic beta cell tumor which is characterized with high insulin content and secretion in response to increasing glucose levels. 4-Methylcatechol (4-MC) is a metabolite of quercetin, which is known as a potential drug for inhibition of tumorigenesis. The aim of this study was to determine the applying doses of 4-methylcatechol (4-MC) for triggening cell death and decreasing the cell function of rat insulinoma INS-1 beta cells. The rate of apoptosis and the amount of insulin in the cell and the secretions were determined by the ELISA method. Betacellulin (BTC) and inhibin beta-A amounts in both the cell and the glucose induced secretion were investigated by Western blotting. Furthermore, BTC, Inhibin beta-A, Ins1, Ins2, and GLUT2 gene expression levels were determined by the by the real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) method. We noted a significant decrease in cell viability, while an increase in apoptotic cell death by 4-MC treatment. It caused a decrease in the secretion of BTC, expressions of both BTC and inhibin beta-A. We showed a decrease in the expressions of Ins1 and GLUT2, while there is no alteration in the level of insulin protein. Insulin ...Continue Reading

References

Oct 1, 1994·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·J R HullyN A Gillett
Sep 1, 1993·The Journal of Clinical Investigation·H YasudaI Kojima
May 4, 2000·Journal of Agricultural and Food Chemistry·S H HäkkinenA R Törrönen
Jun 15, 2000·Journal of Endocrinological Investigation·P FlorioF Petraglia
Dec 6, 2001·Endocrine-related Cancer·S Pelengaris, M Khan
Jan 30, 2002·Experimental Biology and Medicine·Ye-Guang ChenShao-Yao Ying
Jun 22, 2002·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Chiho KanamaruToshiro Fujita
Sep 27, 2002·Experimental Biology and Medicine·Corrine WeltAlan Schneyer
Apr 5, 2003·The Journal of Pharmacology and Experimental Therapeutics·Kyoji MoritaYoshinari Ohnishi
Dec 6, 2003·Science·Morris F White
Apr 26, 2006·Experimental Biology and Medicine·Ye-Guang ChenShao-Yao Ying
Feb 19, 2009·American Journal of Physiology. Endocrinology and Metabolism·Armelle LeturqueMaude Le Gall
Feb 8, 2011·Neuropeptides·Selda Gezginci-Oktayoglu, Sehnaz Bolkent
Sep 23, 2011·Apoptosis : an International Journal on Programmed Cell Death·Selda Gezginci-Oktayoglu, Sehnaz Bolkent
Jan 21, 2014·Seminars in Cell & Developmental Biology·Maik DahlhoffMarlon R Schneider
Feb 3, 2015·Cell Biology International·Chunjin LiXu Zhou

❮ Previous
Next ❯

Citations

Jan 25, 2020·The Journal of Pharmacy and Pharmacology·Ayse Karatug KacarSehnaz Bolkent

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA

Software Mentioned

GraphPad Prism
Carestream MI
Kodak
GraphPad

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Adenoma, Islet Cell

Islet Cell Adenoma arises in the islet cells, which are insulin producing cells of the pancreas. These tumors can be either malignant or benign. Discover the latest research on Islet Cell Adenoma here.